These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 4022786)

  • 1. [Blood picture changes in rats after 90Y-citrate administration].
    Kutzner J; Eckmann A; Grimm W
    Nuklearmedizin; 1985 Apr; 24(2):87-9. PubMed ID: 4022786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography.
    Rösch F; Herzog H; Plag C; Neumaier B; Braun U; Müller-Gärtner HW; Stöcklin G
    Eur J Nucl Med; 1996 Aug; 23(8):958-66. PubMed ID: 8753686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of pharmacokinetics of yttrium-86 radiopharmaceuticals with PET and radiation dose calculation of analogous yttrium-90 radiotherapeutics.
    Herzog H; Rösch F; Stöcklin G; Lueders C; Qaim SM; Feinendegen LE
    J Nucl Med; 1993 Dec; 34(12):2222-6. PubMed ID: 8254415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic dosimetry of bone marrow: induction of micronuclei in reticulocytes after exposure to 32P and 90Y.
    Lenarczyk M; Goddu SM; Rao DV; Howell RW
    J Nucl Med; 2001 Jan; 42(1):162-9. PubMed ID: 11197968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological dosimetry of bone marrow for incorporated yttrium-90.
    Goddu SM; Howell RW; Giuliani DC; Rao DV
    J Nucl Med; 1998 Mar; 39(3):547-52. PubMed ID: 9529309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changing of organ distribution of radioactive yttrium in rats by varying amounts of carrier].
    Kutzner J; Alfter G; Grimm W
    Nuklearmedizin; 1986 Apr; 25(2):78-80. PubMed ID: 3714515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody (BrE-3).
    DeNardo GL; Kroger LA; DeNardo SJ; Miers LA; Salako Q; Kukis DL; Fand I; Shen S; Renn O; Meares CF
    Cancer; 1994 Feb; 73(3 Suppl):1012-22. PubMed ID: 8306243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
    Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA
    Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 90Sr-90Y biokinetics at incorporation determine the radiation burden to bone marrow.
    Stevenson AF
    Indian J Exp Biol; 2000 Mar; 38(3):222-4. PubMed ID: 10927862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraperitoneally administered 90Y-labelled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: problems encountered and possible solutions.
    Hird V; Stewart JS; Snook D; Dhokia B; Coulter C; Lambert HE; Mason WP; Soutter WP; Epenetos AA
    Br J Cancer Suppl; 1990 Jul; 10():48-51. PubMed ID: 2383480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 90Y-microspheres on liver tumors: comparison of intratumoral injection method and intra-arterial injection method.
    Lin WY; Tsai SC; Hsieh JF; Wang SJ
    J Nucl Med; 2000 Nov; 41(11):1892-7. PubMed ID: 11079501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula S; Goldsmith SJ; Hamacher KA; Kostakoglu L; Konishi S; Milowski MI; Nanus DM; Bander NH
    J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. gamma-Interferon administration after 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies.
    Thomas GE; Esteban JM; Raubitschek A; Wong JY
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):529-34. PubMed ID: 7852116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The triboluminescence of the blood and the brain cellular elements in rats exposed to X irradiation in doses causing bone marrow, intestinal and cerebral syndromes].
    Annenkova SV; Dvoretskiĭ AI; Baraboĭ VA; Orel VE; Dziatkovskaia NN
    Radiobiologiia; 1992; 32(2):244-6. PubMed ID: 1598397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intralesional radioimmunotherapy with Yttrium-90-labeled human monoclonal IgM in nude mice bearing human tumor xenografts.
    Borchardt PE; Vriesendorp HM; Freedman RS; Quadri SM
    Cancer Biother Radiopharm; 2004 Feb; 19(1):43-51. PubMed ID: 15068610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological dosimetry after yttrium-90 citrate colloid radiosynoviorthesis.
    Voth M; Klett R; Lengsfeld P; Stephan G; Schmid E
    Nuklearmedizin; 2006; 45(5):223-8. PubMed ID: 17043734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bone-seeking behavior of rhenium and yttrium complexes].
    Kutzner J; Becker M; Grimm W
    Nuklearmedizin; 1983 Jun; 22(3):162-5. PubMed ID: 6622263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yttrium-90 citrate colloid for radioisotope synovectomy.
    Bowen BM; Darracott J; Garnett ES; Tomlinson RH
    Am J Hosp Pharm; 1975 Oct; 32(10):1027-30. PubMed ID: 1190215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.